Benign prostatic hyperplasia: Shared care between urologist and general practitioner;Benign prostatahyperplasi: Delt omsorg mellom urolog og allmennlege

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 3, 1997, Pages 389-393

  Talseth, Trygve ^a   Hedlund, Hans ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; PHENOXYBENZAMINE; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; TERAZOSIN;

DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; PROSTATE HYPERTROPHY; SHORT SURVEY; SYMPTOMATOLOGY; URODYNAMICS;

DIAGNOSIS, DIFFERENTIAL; FAMILY PRACTICE; HUMANS; MALE; PROSTATIC HYPERPLASIA; UROLOGY;

EID: 0031028209     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kirby R, Fitzparick J, Kirby M, Fitzpatrick A. Shared care for prostatic diseases. Oxford: Isis Medical Media, 1994.
2. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308.
3. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469-71.
4. Diokno AC, Brown MB, Goldstein N, Herzog AR. Epidemiology of bladder emptying symptoms in elderly men. J Urol 1992; 148: 1817-21.
5. Hald T. Urodynamics in benign prostate hyperplasia. A survey. Prostate 1989; (suppl 2): 69-77.
6. Abrams P. New words for old: lower urinary tract symptoms for «prostatism». BMJ 1994; 308: 929-30.
7. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993: 42: 36-40.
8. Abrams P, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979; 51: 129-34.
9. Hansen MV, Zdanowski A. The value of a patient administered home flow test compared to office uroflowmetry in the evaluation of prostatism patients. Neurourol Urodyn 1994; 113: 452-3.
10. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9.
11. 1-adrenoceptor selectivity? Br J Urol 1995; 76 (suppl 1): 47-55.
12. 1-adrenoceptor selectivity: clinical or theoretical benefit? Br J Urol 1995; 76 (suppl I): 57-61.
13. Eri LM, Tveter KJ. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923-34.
14. Chapple CR, Scott M, Abrams P, Christmas TJ, Milroy EJ. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285-94.
15. Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J et al. Proscar: five-year experience. Eur Urol 1995; 28: 304-9.
16. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631-7.
17. Tammela TLJ, Kontturi MJ. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993; 149: 342-4.
18. Kirby RS, Bryan J, Eardley I, Christmas TJ, Liu S, Holmes SAV et al. Fmasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation. Br J Urol 1992, 70: 65-72.
19. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
20. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Eng J Med 1996; 335: 533-9.
21. McConnell JD. Benign prostatic hyperplasia: hormonal treatment. Urol Clin North Am 1995; 22: 387-400
22. Fitzpatrick JM, Lynch TJ. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am 1995, 22: 407-12.
23. Eri LM, Tveter KJ. A prospective placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 90-4.